abstract |
[Problem] To provide a medicine in which problems associated with the use of L-DOPA in treating Parkinson's disease, for example, poor retentivity in blood are improved. [Solution] By incorporating L-DOPA in the form of a block copolymer [PEG-b-poly(3,4-hydroxy protected L-DOPA)] into a carrier, the retentivity of the medicine in blood is significantly improved. |